# Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice

Magali Monnoye, Xufei Zhang, Mahendra Mariadassou, Fabienne Beguet-Crespel, Nicolas Lapaque, Christine Heberden, Véronique Douard

<figure><img src="image_1.png" /></figure>

## To cite this version:

Magali Monnoye, Xufei Zhang, Mahendra Mariadassou, Fabienne Beguet-Crespel, Nicolas Lapaque, et al. Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice. Frontiers in Immunology, 2021, 12, 10.3389/fimmu.2021.742584. [https://doi.org/10.3389/fimmu.2021.742584](https://doi.org/10.3389/fimmu.2021.742584).

HAL Id: hal-03634400

https://hal.inrae.fr/hal-03634400

Submitted on 7 Apr 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

Check for
updates

# Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice

Xufei Zhang<fnref n="1" />, Magali Monnoye<fnref n="1" />, Mahendra Mariadassou², Fabienne Beguet-Crespel<fnref n="1" />, Nicolas Lapaque<fnref n="1" />, Christine Heberden<fnref n="1" /> and Veronique Douard<fnref n="1" />*

**OPEN ACCESS**

**Edited by:**
Dunfang Zhang,
Sichuan University, China

**Reviewed by:**
Jiaja Han,
Chinese Academy of Medical
Sciences and Peking Union Medical
College, China
Xikun Zhou,
Sichuan University, China

*Correspondence:
Véronique Douard
veronique.douard@inrae.fr

**Specialty section:**
This article was submitted
to Inflammation,
a section of the journal
Frontiers in Immunology

**Received:** 16 July 2021
**Accepted:** 11 October 2021
**Published:** 27 December 2021

**Citation:**
Zhang X, Monnoye M, Mariadassou M, Beguet-Crespel F, Lapaque N, Heberden C and Douard V (2021) Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice. *Front. Immunol.* 12:742584.
doi: 10.3389/fimmu.2021.742584

A causal correlation between the metabolic disorders associated with sugar intake and disruption of the gastrointestinal (GI) homeostasis has been suggested, but the underlying mechanisms remain unclear. To unravel these mechanisms, we investigated the effect of physiological amounts of fructose and glucose on barrier functions and inflammatory status in various regions of the GI tract and on the cecal microbiota composition. C57BL/6 mice were fed chow diet and given 15% glucose or 15% fructose in drinking water for 9 weeks. We monitored caloric intake, body weight, glucose intolerance, and adiposity. The intestinal paracellular permeability, cytokine, and tight junction protein expression were assessed in the jejunum, cecum, and colon. In the cecum, the microbiota composition was determined. Glucose-fed mice developed a marked increase in total adiposity, glucose intolerance, and paracellular permeability in the jejunum and cecum while fructose absorption did not affect any of these parameters. Fructose-fed mice displayed increased circulation levels of IL6. In the cecum, both glucose and fructose intake were associated with an increase in *Il13*, *Ifnγ*, and *Tnfα* mRNA and MLCK protein levels. To clarify the relationships between monosaccharides and barrier function, we measured the permeability of Caco-2 cell monolayers in response to *Ifnγ*+*TNFα* in the presence of glucose or fructose. *In vitro*, *Ifnγ*+*TNFα*-induced intestinal permeability increase was less pronounced in response to fructose than glucose. Mice treated with glucose showed an enrichment of *Lachnospiraceae* and *Desulfovibrionaceae* while the fructose increased relative abundance of *Lactobacillaceae*. Correlations between pro-inflammatory cytokine gene expression and bacterial abundance highlighted the potential role of members of *Desulfovibrio* and *Lachnospiraceae* NK4A136 group genera in the inflammation observed in response to glucose intake. The increase in intestinal inflammation and circulating levels of IL6 in response to fructose was observed in the absence of intestinal permeability modification, suggesting that the intestinal permeability alteration does not precede the onset of metabolic outcome (low-grade inflammation,

<footnote n="1">¹ Université Paris-Saclay, INRAE, AgroParisTech, MICALIS Institute, Jouy-en-Josas, France, ² Université Paris Saclay, INRAE, MalAGE, Jouy-en-Josas, France</footnote>
hyperglycemia) associated with chronic fructose consumption. The data also highlight the deleterious effects of glucose on gut barrier function along the GI tract and suggest that *Desulfovibrioaceae* and *Lachnospiraceae* play a key role in the onset of GI inflammation in response to glucose.

Keywords: glucose, fructose, Caco-2, *Desulfovibrio*, paracellular permeability, pro-inflammatory cytokines

INTRODUCTION

Increase in consumption of sugar (mainly sucrose and high fructose corn syrup-containing soft drinks) has been tightly linked to the surge in metabolic diseases such as obesity, non-alcoholic fatty liver disease, hypertriglyceridemia, type 2 diabetes, and metabolic syndrome (1-6). Sucrose and high-fructose corn syrup are both composed of near-equal amounts of glucose and fructose. There is rising evidence that in these sweeteners, fructose and, in a lesser extent, glucose favor the development of metabolic diseases associated with sugar intake (7-10). Obesity-associated chronic low-grade inflammation characterized by high levels of plasmatic inflammatory markers [C-reactive protein, interleukin 6 (IL6) or tumor necrosis factor α (TNFα)] largely contributes to the development of the obesity-related chronic metabolic diseases (11-13). The origins of the low-grade inflammation observed in metabolic disorders are still not entirely understood. However, recent work showed that the gut contributes to its establishment (12, 14). Gut barrier defects (increased permeability, mucosal inflammation and dysbiosis) favor the translocation of microbial products, which promulgate inflammation to the peripheral tissues (15, 16). To maintain the intestinal barrier function, the preservation of the paracellular permeability is essential. The tight junctions (TJ) primarily regulate the barrier formed between epithelial cells apically. Occludin, claudins, junctional adhesion molecules (JAMs), and zonula occludens (ZO) are the main TJ proteins that form the TJ complex. The intestinal paracellular permeability depends on TJ protein expression levels, their phosphorylation status, and their subcellular organization (17-19). While the events involved in the loss of the barrier function are not fully understood, cytokines such as IL1β, IL13, interferon gamma (IFNγ), and TNFα have been shown to remodel the TJ architecture and thus

increase paracellular permeability (20-22). Other factors, such as the enteric nervous system (ENS), also participate in the regulation of the intestinal permeability. The ENS is constituted of enteric neurons, which are surrounded by large populations of enteric glial cells (EGCs). Several studies suggested that glial fibrillary acidic protein (GFAP)-positive EGCs participate in the regulation of the inflammatory response and in the regulation of the integrity of the gut epithelium (23).

Although less well explored than in the context of high fat diet, the role of intestinal permeability is also suspected to be essential for the development of metabolic disorders resulting from high sugar intake. Luminal glucose has long been known to regulate intestinal paracellular permeability *in vitro* in Caco-2 cells (24), and *in vivo* in the jejunum of rats (25, 26) and humans (27). Recently, in the context of hyperglycemia, plasma glucose has been demonstrated to alter the transcription of TJ proteins and intestinal permeability *via* its retro-transport into enterocytes by the basolateral glucose transporter GLUT2 (28). The effect of dietary fructose on intestinal permeability is less clear and the association of its high intake with systemic inflammation has been inconsistent (29, 30). Fructose consumption has been reported to decrease occludin protein levels in the mouse small intestine (31, 32) and has been associated with endotoxemia, suggesting an altered intestinal barrier function (32, 33). However, the direct effect of fructose-induced alteration of intestinal barrier function on the onset of metabolic outcome in response to chronic fructose intake remains unexplored. Indeed, fructose impact on intestinal permeability has scarcely been studied and often in association with high levels of dietary lipids (34) or non-physiological amounts of fructose (29). Since fructose is also associated with increase in glycemia (29, 35), which is associated with increase in intestinal permeability in a GLUT2-dependent manner (28), the direct role of luminal fructose on the gut barrier function must be questioned.

In this study, using dietary glucose as a positive control, we aim to clarify the impact of fructose on the intestinal permeability prior to the onset of hyperglycemia. Fructose absorption has been reported to take place in the small intestine (36). However, a recent study showed that high fructose intake can overwhelm the sugar absorptive capacity of the small intestine and non-absorbed fructose can reach the lower intestine (37). Therefore, we assessed the effects of chronic intake of physiological amounts of fructose on the paracellular permeability of the small intestine, the cecum, and the colon. In order to clarify the mechanism involved, we evaluated changes in gut microbiota composition, expression of TJ proteins, and

<footnote>**Abbreviations:** DMEM, Dulbecco's modified Eagle's medium; ECL-HRP, Enhanced chemiluminescent horseradish peroxidase; EGC, Enteric glial cells; ENS, Enteric nervous system; FBS, Fetal bovine serum; FITC-SA, Fluorescein isothiocyanate-Sulfuric acid; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GFAP, Glial fibrillary acidic protein; GI, Gastrointestinal; GLUT2, Facilitated glucose transporter 2; GLUT5, Facilitated glucose/fructose transporter 5; IFN-g, Interferon gamma; IL1β, Interleukin 1 beta; IL10, Interleukin 10; IL6, Interleukin 6; IL13, Interleukin 13; IL22, Interleukin 22; ILC1 or 2, Group 1 or 2 innate lymphoid cells; JAMs, Junctional adhesion molecules; MLC, Myosin light chain; MLCK: Myosin light chain kinase; OGTT, Oral glucose tolerance test; OTU: Operational taxonomic units; PCoA, Principal coordinates analysis; SGLT1, Apical sodium/glucose cotransporter; sPLS-DA: Sparse partial least squaresdiscriminant analysis; TEER, Transepithelial electrical resistance; Th1, Lymphocytes type 1 helper; Th2, Lymphocytes type 2 helper; Th17, Lymphocytes type 17 helper; TJ, Tight junction; TNF-a, Tumor necrosis factor alpha; Treg, Regulatory T cells; ZO, Zonula occludens.</footnote>
inflammatory and ENS markers. Our results demonstrate that fructose does not increase the intestinal permeability in the small intestine where its luminal concentration is the highest. Moreover, while the inflammation of the cecum was similar in fructose- and glucose-fed mice, the intestinal paracellular permeability increased only in response to chronic intake of glucose, but not of fructose. Finally, we showed that in an *in vitro* Caco-2 cell model, glucose but not fructose enhances inflammation-induced permeability increase.

# MATERIALS AND METHODS

## Animals and Experimental Design

This study was conducted in accordance with French guidelines on animal experimentation and validated by the Ethics Committee in Animal Experiment of INRA Jouy-en-Josas (Comethea, registration number: APAFIS#1620-2015102618572930v2). Male C57BL/6NRj mice (7 weeks old, Janvier Labs, St Bertevin, France) were individually housed and maintained in 12-h light/12-h dark cycle. Mice received, before and during the experimental procedure, a chow diet meeting their complete need (Ssniff, Soest, Germany). After 2 weeks of adaptation, the mice received as drinking solution either water (Control), 15% glucose (Glucose), or 15% fructose (Fructose) for 9 weeks. The duration and sugar concentration were based on previous studies showing modest metabolic outcomes in response to 15% fructose (38–40). Food and water were provided *ad libitum*. Body weight, drink, and food intakes were measured three times per week. Caloric intake measurement was calculated based on the daily average intake (in grams and milliliters) of chow (3.27 kcal/g of chow) and drinking solution (0.6 kcal/ml of glucose or fructose solution), respectively. After 9 weeks, non-starved mice were euthanized. Cardiac blood was collected under anesthesia into EDTA tubes, centrifuged (4°C, 2,000g, 15 min), and stored at –80°C for cytokine analysis. Non-flushed 2-cm sections of jejunum, cecum, and colon were sampled and stored in Krebs buffer for instant intestinal permeability measurement in Ussing chambers. Flushed sections of jejunum, cecum, and colon were sampled, flash frozen in liquid nitrogen, and stored at –80°C for protein and mRNA analysis. The cecal content was sampled and stored at –80°C for bacterial DNA analysis. Liver was sampled and weighed.

## Oral Glucose Tolerance Test

Oral glucose tolerance test (OGTT) was performed after 8 weeks of exposure to 15% glucose or 15% fructose beverage. Glucose was orally administered (2 g/kg body weight) to the mice after 12 h fasting, during which food as well as fructose- or glucose-drinking solutions were removed and replaced with water.

## Ussing Chamber Permeability Measurement

Shortly after sampling, intestinal sections of jejunum, cecum, and colon were opened along the mesenteric border and mounted in Ussing chambers (Physiologic Instruments, San Diego, USA) using an appropriate slider area size (0.2 cm² for jejunum and cecum, 0.1 cm² for colon). The mucosal side of the tissue was

exposed to oxygenated Krebs-mannitol (10 mM) buffer, while the serosal side was exposed to oxygenated Krebs-glucose (10 mM) buffer. All buffers were maintained at 37°C. Fluorescein isothiocyanate-sulfuric acid (FITC-SA; Thermo Fisher Scientific, France) was used as a marker of TJ paracellular permeability. After adding FITC-SA (40 µg/ml) to the mucosal chamber, 100 µl was collected in duplicate from the serosal chamber every 15 min for 2 h. The concentration of FITC-SA was measured *via* fluorescence at excitation 485 nm and emission 538 nm. Paracellular permeability was measured by the flux of FITC-SA expressed as ng/cm²/h.

## RNA Extraction and Quantitative Real-Time PCR

The total mRNA from jejunum, cecum, and colon sections were extracted using MirVana miRNA isolation kit (Thermo Fisher Scientific, France). Two micrograms of mRNA was reverse transcribed using the High Capacity Complementary DNA Reverse Transcription Kit (Thermo Fisher Scientific, France) as described previously (41). Quantitative real-time PCR (qRT-PCR) was performed using SYBR-Green® PCR 2X Master Mix (Applied-Biosystems, France) to quantify the gene expression of TJ proteins and inflammatory markers. β-actin was used as a housekeeping gene to normalize the mRNA abundance of each target gene (primers are listed in **Table S1**). Expression values of target genes were calculated based on the comparative threshold cycle (Ct) method to generate ΔCt values. The relative abundance of each mRNA in each sample was then normalized according to the equation: Relative Quantity $RQ = 2^{-\Delta\Delta C_t}$.

## Protein Extraction and Western Blot

Total protein from cecum sections was extracted using RIPA buffer (Sigma-Aldrich, France) with 4% and 10% protease inhibitor (Roche, Sigma-Aldrich, France) and phosphatase (Roche, Sigma-Aldrich, France), respectively, and quantified using the RC DC Protein Assay kit (Biorad, France). Western blot analyses were performed using 50 µg of intestine and membranes were probed with polyclonal antibodies against myosin light-chain kinase (MLCK) (Sigma-Aldrich, France) diluted 1:2,000 and then stripped and reprobed with mouse anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) antibody (Sc-365062 Santa Cruz, USA). The blots were revealed using enhanced chemiluminescent horseradish peroxidase substrate (ECL-HRP Thermo Fisher Scientific, France) and visualized using ChemiDoc MP imaging system (Bio-Rad, France). All bands were digitally captured and densitometry analysis was performed using Image Lab 5.0 software (Bio-Rad, France).

## Immunoprecipitation of GFAP

Three hundred micrograms of cecum protein extract was incubated for 2 h at RT and then overnight at 4°C with rabbit monoclonal anti-GFAP antibody (1:40, Ab68428, Abcam, France). The immune complexes were captured with 50% Protein A Agarose beads (Cell Signaling, Saint Quentin Yvelines, France) on a rotator for 2 h at RT. After
centrifugation (4°C, 20,000g, 5 min), the precipitates were washed three times with RIPA buffer. The final pellets were suspended in 30 µl of 2× loading buffer and incubated at 95°C for 15 min. The entire suspension was loaded onto a SDS-PAGE gel, and the Western blot for GFAP (1:10,000) was performed as described above and using peroxidase-labeled secondary anti-rabbit antibody (1:400, Abcam, France). Blot image analysis was performed as described above.

## Plasma Analysis

IL6, TNFα, and IFNγ levels were determined by ELISA (Peprotech, France) using 50 µl of plasma diluted 1:2.

## Caco-2 Cell Culture and TEER Measures
### In Vitro

Caco-2BBe cells (kindly donated by JR. Turner, Harvard Medical School) and cultured in high-glucose (25 mM) Dulbecco's modified Eagle's medium (DMEM, Gibco, Thermo Fisher Scientific, France) with 10% fetal bovine serum (FBS, Sigma-Aldrich, France) and 10 ng/ml human transferrin. Caco-2BBe cells were seeded at $2 \times 10^5$ cells/well and differentiated as monolayers on collagen-coated polycarbonate membrane transwells with 0.3-µm pores (Thermo Fisher Scientific, France) for 15-18 days after confluence. DMEM medium was renewed every 3 days. Transepithelial resistance (TEER) was measured every 3 days with Voltohmometer instrument (Millicell-ERS, Merck Millipore, France). In experiment 1, after 15-18 days (when TEER was about 250 Ω.cm² and stable), the culture medium was changed to 25 mM glucose or 25 mM fructose medium with 10% FBS and 10 ng/ml transferrin in both basal and apical chambers 1-day prior to cytokine treatment (D0). In experiment 2, to determine whether glucose and fructose were necessary for IFN-γ/TNF-α-induced changes in TEER, at D0, the 25 mM glucose medium was changed to 1 mM glucose or 1 mM fructose medium. At D1, recombinant human IFN-γ (Peprotech, France) was added into glucose or fructose medium (10 ng/ml concentration) in the basal chamber for 24 h. At D2, new medium containing 50 ng/ml TNF-α (Peprotech, France) was placed in the basal chamber. Both IFN-γ and TNF-α treatments were done without manipulating the apical chamber. The TEER was measured before adding TNF-α and every hour afterward for 6 h. Results were expressed as percent of TEER of control monolayers (cells exposed to glucose or fructose for 48h without IFN-γ and TNF-α) of the same experiment.

## Microbiota DNA Extraction and 16S
### DNA Sequencing

Total DNA was extracted from cecal content samples using GNOME DNA isolation kit (MP Biomedicals, Strasbourg, France). The V3-V4 hypervariable region of the bacterial 16S rDNA was amplified by PCR (forward primer: 5'-CTTTCC CTACACGACGCTCTTCCGATCTACGGRAGGCAGCAG-3', reverse primer: 5'-GGAGTTCAGACGTGTGCTCTTCCG ATCTTACCAGGGTATCTAATCCT-3'; 94°C for 1 min and then 30 cycles at 94°C for 1 min, 65°C for 1 min, and 72°C for 1 min before a final step at 72°C for 10 min) (42). After quality

checking by electrophoretic 2% agarose gel migration, obtained amplicons were sequenced using Illumina MiSeq technology (GenoToul platform, Toulouse, France). Paired-end reads obtained from MiSeq sequencing were analyzed using the Galaxy-supported pipeline named FROGS [Find, Rapidly, OTUs (operational taxonomic units) with Galaxy Solution] (43). For the preprocessing, reads with length ≥ 380 bp were kept. The clustering and chimera removal tools followed the guidelines of FROGS (43). Assignment was performed using SILVA 16S. OTUs with abundances lower than 0.005% were removed from the analysis (44). Real-time PCR analyses were performed to quantify *Desulfovibrio* genus abundance. Quantitative PCR reactions were conducted in a final volume of 25 µl using SYBR-Green® PCR 2X Master Mix (Applied-Biosystems, France) and with 0.2 µM final concentration of each primer (DSV691-F CCGTAGATATCTGGAGGAACATCAG and DSV826-R: ACATCTAGCATCCATCGTTTACAGC) and 5 µl of DNA samples (45).

## Bacteria In Vitro Culture

*Bacteroides vulgatus* (ATCC 8482) and *Lactobacillus johnsonii* (strain CIP 103620) were grown in DP2 growth medium enriched with 5 g/L of glucose or 5 g/L of fructose (46). *Desulfovibrio vulgaris* subsp. vulgaris (DSM 644) was grown in appropriate Medium 63 containing either glucose (5 g/L) or fructose (5 g/L). All bacteria were cultured in anaerobic condition at 37°C using the Hungate culture method. For each bacterial species, 24 h growth media (containing no fructose) were inoculated with a 1:9 dilution to a duplicate set of young culture containing glucose or fructose. The growth of *B. vulgatus* and *L. johnsonii* was measured every 30 min or 1 h by absorbance (A660) for 8-10 h. For *D. vulgaris* after 4 h and 9 h, the DNA was extracted using GNOME DNA isolation kit (MP Biomedicals, Strasbourg, France) and the growth was measured by qPCR using the primers DSV691-F CCGTAGATATCTGGAGGAACATCAG and DSV826-R: ACATCTAGCATCCATCGTTTACAGC. The total number of bacteria was inferred from averaged standard curves as previously described (47).

## Statistical and Microbiota Analysis

Statistical analysis was performed using GraphPad Prism software (v7; San Diego, CA). All data were analyzed using Kruskal-Wallis test followed by a Dunn's multiple comparison test. 16S rDNA sequencing data were analyzed using the Phyloseq package in R and custom scripts as described previously (48). Briefly, 16S sequencing data were analyzed using the Phyloseq (49), ggplot2 (50), DESeq2 (51), and custom scripts. Samples were rarefied to even sampling depths before α-diversities (observed richness and Inverse Simpson) and β-diversity (Bray-Curtis) analysis. Principal coordinates analysis (PCoA) was performed on Bray-Curtis dissimilarities. α-diversity data were analyzed using Kruskal-Wallis test. Permutational multivariate analysis of variance (PERMANOVA) test was performed on the Bray-Curtis matrices using 999 random permutations and at a significance level of 0.01. Phylum and family abundances data were compared using Kruskal-Wallis test. Raw, unrarefied OTU (also named clusters) counts were used to produce
relative abundance graphs and to find taxa with significantly different abundances between two groups. DESeq2 was used to estimate abundance log-fold changes (logfc) between glucose/ control, fructose/control, or glucose/fructose groups. Clusters were selected based on effect size (fold change (FC) > 1.5 or FC < 1/1.5) and adjusted *p*-value (<0.05). Pro-inflammatory cytokine gene expression levels (TNFα, IL13, IL22, and IFNγ) and normalized bacterial abundance (52) were integrated and analyzed using Data Integration Analysis for Biomarker discovery using a Latent Components (DIABLO) method implemented in R mixOmics package (53). Correlation analysis between cytokines gene expression and bacterial species abundance was performed using the multiblock analysis DIABLO (block.splsa function) (54). Horizontal sparse partial least squares-discriminant analysis (sPLS-DA) was used to integrate the relative abundances of OTU (clusters) with the cytokine gene expression levels. To perform the analysis, 5% of the OTU (which were the most involved in the group discrimination) were selected. The level of correlation between the OTU and the cytokine gene expression level was determined and the resulting correlation network showing only positive (>0.83) and negative (<=0.83) correlations between the selected variables was built in DIABLO.

RESULTS

Glucose and Fructose Modified Differently Physiological Parameters

Mice-fed glucose solution gained 15% more weight than the
fructose- and water-drinking mice after 9 weeks of experiment
(Figure 1A). This likely resulted from a significantly higher total
daily calorie intake by the glucose-drinking mice when compared
to mice receiving fructose or water solutions (Figure 1B). Eight
weeks of chronic intake of glucose impaired glucose tolerance both
in the individual points of the curve (Figure 1C) and in the AUC
(Figure 1D) when compared to control and fructose groups. Nine
weeks of chronic intake of fructose was associated with a significant
increase in plasmatic levels of IL6 when compared to the control
group (Figure 1E) while the plasmatic levels of TNFα and IFNγ
remained unchanged among the three groups (Figures 1F, G).
After 9 weeks, glucose-drinking mice also displayed a significantly
higher visceral adiposity (2.94% ± 0.19) than the fructose-drinking
(1.66% ± 0.22) or control (1.52% ± 0.14) groups. There was no
difference in liver weight among the three groups (data not
shown). Despite a major effect of glucose intake on body weight
gain and glucose tolerance, only fructose initiated an increase in
circulating levels of pro-inflammatory cytokines.

Glucose But Not Fructose Altered
Intestinal Permeability

Earlier studies suggested that barrier defects contribute to the
establishment of dietary-associated chronic low-grade
inflammation (55, 56). To determine whether fructose-induced
systemic inflammation was associated with alteration of intestinal
permeability, we evaluated this parameter in the small (jejunum)
and large intestine (cecum and proximal colon) ex vivo using the

Ussing chamber system. Nine weeks of glucose consumption significantly increased paracellular permeability to FITC-SA in both jejunum and cecum when compared to the fructose groups (Figures 2A1, A2). Glucose intake also lead to a trend toward increased permeability in jejunum and cecum when compared to the control group. In the colon, neither glucose nor fructose changed the paracellular permeability (Figure 2A3). In the jejunum, glucose-induced changes in permeability were not associated with changes in *Mlck* and TJ protein expression levels (Figure 2B1). Of the pro-inflammatory cytokines tested, only *Il1β* expression was significantly upregulated in the jejunum of the mice consuming glucose when compared to the control and fructose groups (Figure 2C1). In the cecum, glucose-induced increase in permeability was associated with a significant increase in *Mlck* expression when compared to the control group (Figure 2B2). In contrast, fructose-drinking mice displayed a significant decrease in expression of *claudin2* and *occludin* relative to the control and glucose groups respectively. In cecum, both glucose and fructose significantly increased the expression of *Tnfa*, *Il13*, *Ifnγ*, and *Il10* when compared to the control group (Figure 2C2). In addition, glucose intake was also associated with a significant increase in *Il22* expression in the cecum when compared to the mice of the control group. Only *Il1β* expression remained unchanged among the three groups. In the colon, fructose moderately increased *claudin2* expression while the expression of the other TJ proteins remained unchanged in response to glucose or fructose (Figure 2B3). Likewise, none of the pro-inflammatory cytokines tested displayed any changes in expression among the three groups (Figure 2C3). *Il6* expression levels remain unchanged among the three groups in the jejunum, cecum, and ileum (data not shown). Western blot showed that in the cecum, MLCK protein level increased significantly in response to glucose and fructose (Figure 3). Thus, in the cecum, both glucose and fructose caused similar upregulation of pro-inflammatory cytokine expression and MLCK protein levels, but only glucose was associated with increased permeability.

In addition to the above gut homeostasis effects, glucose and
fructose intake significantly upregulated in jejunum the
expression of the apical sodium/glucose cotransporter, *Sglt1*,
and of the basolateral glucose transporter, *Glut2*, but only
fructose drastically upregulated the expression of its apical
transporter, *Glut5* (Figure S1A). In the cecum, glucose intake
was associated with an increase in expression levels of both
glucose transporters, *Sglt1* and *Glut2*, while the fructose intake
did not change *Glut5*, *Sglt1*, or *Glut2* mRNA levels (Figure S1B).
These data suggest that glucose and fructose transport levels are
likely different between the jejunum and cecum.

Fructose, But Not Glucose, Affected the
EGC of the ENS

Usually, pro-inflammatory cytokines such as IL13, TNFα, and IFNγ are associated with increased paracellular permeability (22, 57). Yet, only glucose, but not fructose increased the permeability in the cecum. To clarify this surprising observation, we investigated the impact of fructose and glucose on the EGCs of the ENS, which has been described as contributing to the
<figure><img src="image_4.png" /></figure>

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

<figure><img src="image_10.png" /></figure>

**FIGURE 1** | Effects of glucose and fructose on body and plasma parameters. (A) Body weight changes during 9 weeks of exposure to glucose or fructose. (B) Average daily caloric intake originating from solid diet or drink solutions. (C) Blood glucose levels during oral glucose tolerance tests. (D) Area under the curve (AUC) of blood glucose levels during OGTT. Plasma levels of (E) IL6, (F) INFγ, and (G) TNFα. All values are means ± SEM; n = 6–8/group. For figures A and C: At each time point, mean data were compared by Kruskal–Wallis test followed by Dunn multiple comparison test. For figures A and C, \* indicates a significant difference between glucose and fructose groups (\*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001) while $^{§}$ indicates a significant difference between glucose and control groups ($^{§}$p < 0.05; $^{§§}$p < 0.01; $^{§§§§}$p < 0.001; $^{§§§§§}$p < 0.0001). For the other figures, means were compared by Kruskal–Wallis test followed by Dunn multiple comparison test and \* indicates a significant difference among the groups (\*p < 0.05; \*\*p < 0.01).

maintenance of epithelial barrier function (36). GFAP protein levels were quantified in full thickness preparation from cecum segment. GFAP protein expression level significantly increased in cecum of mice drinking fructose when compared to the cecum of control mice (Figures 4A, B), suggesting active gliosis in response to fructose.

In Pro-Inflammatory Context,
Intestinal Permeability Changes
in Response to Fructose Are Less
Pronounced Than With Glucose

To investigate further the differential effects of glucose and
fructose on intestinal permeability and to determine whether
<figure><img src="image_11.png" /><figcaption>**FIGURE 2** | Paracellular permeability, intestinal permeability, and inflammatory marker expression levels in various regions of the gut. *Ex vivo* paracellular permeability to FITC-sulfonic acid measured in the jejunum (A1), cecum (A2), and colon (A3). The mRNA expression levels of gene encoding for tight junction proteins in the jejunum (B1), cecum (B2), and colon (B3). The mRNA expression levels of inflammatory cytokine markers measured in the jejunum (C1), cecum (C2), and colon (C3). The mRNA level data were normalized to the control group. All values are means ± SEM; *n* = 5–8/group. Means were compared by Kruskal–Wallis test followed by Dunn multiple comparison test. \* indicates significant differences among groups (\*p < 0.05 and \*\*p < 0.01). FITC-SA: Fluorescein isothiocyanate-sulfuric acid; II1β: Interleukin 1 beta; II10: Interleukin 10; II13: Interleukin 13; II22: Interleukin 22; Ifnγ: Interferon gamma; Mlck: Myosin light-chain kinase; ZO-1: Zonula occludens-1; Tnfa: Tumor necrosis factor alpha.</figcaption></figure>

the two monosaccharides act directly on enterocytes, we used the Caco-2 cell line since these cells grow as polarized monolayers and express sugar transporters at the apical membrane (58). They have been extensively used as a model to study TJ regulation in response to pro-inflammatory cytokines (22, 59, 60). The permeability of tight junctions was measured by monitoring TEER. After differentiation of the Caco-2, enterocyte monolayers were cultured in the presence of 25 mM glucose or fructose for 48 h. Then, the TEER was measured in response to IFNγ priming followed by TNFα treatment. In the absence of pro-inflammatory challenge, 25 mM fructose did not affect the TEER when compared to 25 mM glucose (Figure S2). In both glucose and fructose culture conditions, TNFα/IFNγ caused a time-dependent decrease in Caco-2 TEER (Figure 5). However, when compared to glucose, fructose significantly attenuated the TEER decrease in response to

cytokine stimulation after 5 h. The lack of effect of TNFα/IFNγ treatment on TEER when the glucose or fructose concentrations were reduced to 1 mM suggests that the sugar metabolism is a key factor enabling pro-inflammatory cytokines to reduce TEER (Figure S2).

Glucose and Fructose Changed the Gut Microbiota Composition

Several studies have reported that diet-induced changes in gut microbiota composition contribute to the intestinal inflammation and alteration of the gut permeability (37). Therefore, we investigated the effects of glucose- and fructose-drinking treatment on the cecal ecosystem composition using microbial 16S rRNA sequencing. The α-diversity was measured at the OTU level using the richness (observed species) and inverse Simpson index. Both parameters showed no significant
<figure><img src="image_12.png" /><figcaption>**FIGURE 3** | Protein expression level of MLCK in the cecum. (A) Representative images of Western blots for MLCK. (B) Relative band intensity of MLCK normalized to GAPDH and expressed relative to the control group. All values are means ± SEM; *p* < 0.05. MLCK, Myosin light-chain kinase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.</figcaption></figure>

<figure><img src="image_13.png" /><figcaption>**FIGURE 5** | The effects of glucose and fructose on barrier function in response to cytokines in Caco-2 cells. Caco-2BBe cells were differentiated on transwells for 17 days after confluence until reaching stable TEER. Cells were cultured for 24 h in the presence of glucose (4.5 g/L)- or fructose (4.5 g/L)-enriched DMEM before exposure to cytokines. The cells were treated, in the presence of glucose or fructose, with 10 ng/ml IFNγ in the basal chamber for 24 h prior to 50 ng/ml TNFα treatment. The TEER was measured for 5 h following introduction of TNFα (= T0). All values are means ± SEM; *p* = 0.001, **p** < 0.05, and #p < 0.0001. $\ddagger$ indicates a significant difference between Fructose+IFNγ/TNFα and Glucose groups (*p* < 0.05; **p** < 0.0001), $\ddagger\ddagger$ indicates a significant difference between Glucose+IFNγ/TNFα and Fructose groups ($\ddagger\ddagger$ *p* < 0.05; $\ddagger\ddagger\ddagger$ *p* < 0.0001), and # indicates a significant difference between Fructose+IFNγ/TNFα and Glucose+IFNγ/TNFα groups ($\ddagger\ddagger\ddagger$ *p* < 0.05).</figcaption></figure>

<figure><img src="image_14.png" /><figcaption>**FIGURE 4** | Protein expression level of GFAP in the cecum. (A) Representative images of Western blots for GFAP obtained from the load of 300 µg of cecal protein extract for each sample. All values are means ± SEM; *p* < 0.05. (B) Band intensity of the glucose and fructose group is expressed relative to the average intensity of the control group. Means were compared by Kruskal-Wallis test followed by Dunn multiple comparison test. * indicates significant differences among groups (*p* < 0.05). GFAP, Glial fibrillary acidic protein.</figcaption></figure>

change in richness and α-diversity of the microbiota in response to glucose or fructose intake (Figures 6A, B). However, PCoA of Bray-Curtis compositional dissimilarity between cecum samples from each group showed a significant separation between the communities in response to glucose and fructose when compared to the control group (*p* = 0.003 and *p* = 0.004, respectively) as well as between glucose and fructose (*p* = 0.007) (Figure 6C). Glucose-drinking mice demonstrated a more significant shift in cecal microbial composition than fructose when compared to the control mice. Firmicutes relative abundance decreased in the glucose group when compared to control while the relative abundance of Proteobacteria increased significantly in the cecal community of the glucose group when compared to control (Figure 6D). At a lower taxonomic level, within the Proteobacteria phylum, the relative abundance of *Desulfovibrioaceae* significantly increased in the cecal content of the glucose group when compared to control groups (Figure 6E). Within the Firmicutes phylum, the fructose intake increased the relative abundance of *Lactobacillaceae* when compared to the glucose group. Within the Bacteroidetes phylum, fructose modestly decreased the relative abundance of *Bacteroidaceae* when compared to the control group. The increase in *Desulfovibrioaceae* indicates that glucose consumption modified microbiota composition towards pro-inflammatory profile while the higher abundance in *Lactobacillaceae* suggests that beneficial microbiota environment was associated with fructose chronic intake.
A

<figure><img src="image_15.png" /></figure>

B

<figure><img src="image_16.png" /></figure>

C

<figure><img src="image_17.png" /></figure>

D

<figure><img src="image_18.png" /></figure>

E

<figure><img src="image_19.png" /><figcaption>**FIGURE 6** | Impact of glucose and fructose on α- and β-diversity of bacterial cecum content. Analysis was based on 16S rDNA sequencing (region V3–V4) of the cecum content collected from control, glucose or fructose mice (n = 6–8/group). (A) Observed species richness and (B) Inverse Simpson Index as indicators of α-diversity. (C) Principal coordinates analysis (PCoA) of Bray-Curtis compositional dissimilarity at the operational taxonomic unit (OTU) level. Each dot represents of one mice. <sup>a, b, c</sup> indicate a significant difference between the groups. Average relative abundance at the (D) phylum and (E) family levels in caecum content of each group. For figures D and E, the average of each group is represented along the X-axis and the Y-axis refers to relative normalized abundances. Alpha-diversity, phylum and family relative abundance data were compared using Kruskal-Wallis test followed by Dunn multiple comparison test. <sup>§</sup> indicate significantly different phyla or family abundances between Glucose and Control (with <sup>§</sup>p < 0.05, <sup>$$$</sup> p<0.001), <sup>*</sup> indicate significantly different family abundances between Fructose and Control (with <sup>*</sup>p <0.05) and <sup>*</sup> indicate significantly different family abundances between Fructose and Glucose (with <sup>*</sup>p < 0.05).</figcaption></figure>

Differential abundance analysis identified 34 significant (p < 0.05) species or clusters that were positively (25 clusters) or negatively (9 clusters) differentially abundant between glucose and control groups (**Figure 7A**). Among them, 7 clusters exhibited a fold change > 32 and 11 of them belong to *Lachnospiraceae* family. This differential analysis also highlighted cluster_4 belonging to the *Desulfovibrio* genus. This cluster related to the most abundant species identified by DESeq2 (base mean = 719, **Table S2**), suggesting that the increase in *Desulfovibrioaceae* abundance in response to glucose identified previously (and confirmed by qRT-PCR) (**Figure S3**) was likely related to the increase in cluster_4 abundance (**Figures 7A, B**). Similarly, 46 species or clusters were positively (33 clusters) or negatively (13 clusters) differentially abundant between fructose and control groups and only 15 of them were similar to those identified as differentially abundant in response to glucose (**Figure 7C**). Among the species showing increased differential abundance in

response to fructose, three species (cluster_253, cluster_208, and cluster_217) belong to the *Lactobacillus* family, which appears as a signature of the fructose intake (**Figures 7B, C**). Six species were positively (among which five species belong to *Lachnospiraceae* family and one, cluster_4, to *Desulfovibrioaceae* family) and seven were negatively (among which the cluster_217 was from *Lactobacillaceae* family) differentially abundant between glucose and fructose groups (**Figure 7B**).

When ingested as liquid, glucose and fructose are not fully absorbed by the enterocytes and reach the lumen of the lower intestine (37, 61). *In vivo*, changes in the abundance of specific bacterial species under glucose or fructose suggest different abilities of the bacteria to use directly these two monosaccharides to promote their growth. We tested this hypothesis for the bacteria that showed differential abundance *in vivo* and that can be grown in culture by assessing their growth *in vitro* in the presence of either glucose or fructose. These bacteria were (1) either representative of bacteria that had an
A

<figure><img src="image_20.png" /></figure>

B

<figure><img src="image_21.png" /></figure>

C

<figure><img src="image_22.png" /></figure>

**FIGURE 7** | Graphic representation of differentially abundant OTUs between Glucose and Control groups (A), Glucose and Fructose groups (B), and Fructose and Control groups (C). Only OTUs (named Cluster) with adjusted values <0.05, estimated fold change >1.5 or <1/1.5, and relative abundance >0.1% in at least half the samples were considered and included in the plots. Each OTU is represented by a bar colored according to its taxonomic classification at the family level. Taxonomy at the genus or species level is also indicated, when available, in **Supplementary Table S2**. A logarithmic scale (log-2) was used for the x-axis.

increased relative abundance in response to both glucose and fructose intake in comparison to the control group (cluster_191 identified as *B. vulgatus*, **Table S2**), (2) bacteria that displayed an enrichment specifically in response to fructose (*L. johnsonii*) characteristic of *Lactobacillus* genus and corresponding to

cluster_253), or (3) bacteria that displayed an enrichment specifically in response to glucose (as *D. vulgaris* characteristic of *Desulfovibrio* genus and corresponding likely to cluster_4). *B. vulgatus*, *L. johnsonii*, and *D. vulgaris* were all able to grow on either glucose- or fructose-containing media (**Figure S4**) and for
all three species, growth was promoted by glucose in microbial culture media when compared to fructose.

## Correlation Between Gene Expression of Inflammatory Markers and Gut Microbiota

Multi-group sPLS-DA was performed to identify the OTU that discriminated for components 1 and 2 between glucose, fructose, and control groups (Figure S5). Using a cutoff of ≥0.6, 25 bacterial species (clusters) were correlated with four pro-inflammatory cytokines' (IL22, IL13, TNFα, and IFNγ) gene expression levels (Figure 8). Two clusters belonging to the *Clostridiales* order were positively linked to three cytokines:

cluster_66 (*Lachnospiraceae* family) correlated to IL22, IFNγ, and IL13 and cluster_372 (*Ruminococcaceae* family) correlated with IL22, TNFα, and IL13. Four other clusters, all members of the *Clostridiales* order, were correlating positively with IL22 and IL13 (cluster_291, cluster_637, cluster_406, and cluster_821) while cluster_95 (*Oscillibacter* genus) was strongly negatively correlated to those. Cluster_4 (*Desulfovibrio* genus) was linked with IL22 and IFNγ while cluster_568 (*Clostridiales vadinBB60* family) was associated with TNFα and IL13. In addition to cluster_95, two other members of the *Bacteroidales* S24-7 group were negatively correlated to IL13 (cluster_490 and _360). Four clusters were also negatively associated to TNFα, among which

<figure><img src="image_23.png" /><figcaption>**FIGURE 8** | Graphic representation of the correlation between cytokine expression levels and relative abundance of bacterial species. Discriminant Clusters (blue circles and cluster ID) and cytokines (green circles and names) were positively (light and dark blue) or negatively (orange and red) connected.</figcaption></figure>
two, cluster_240 (Ruminococcaceae family) and cluster_389 (Lachnospiraceae family), display a negative fold change in response to fructose intake (Figure 7C). Interestingly cluster_4, cluster_66, cluster_637, cluster_40 (Lachnospiraceae family), and cluster_80 (Bacteroidales S24-7 group family) were among the bacterial species significantly upregulated in response to glucose (Figures 7A, B), highlighting the potential role of glucose-induced gut microbiota changes in the development of inflammation in the epithelium of the lower GI tract.

DISCUSSION

In the current study, we provide experimental evidence that chronic intake of enriched fructose beverage did not alter the paracellular permeability in the jejunum, cecum, and colon and this despite a clear increase in systemic and cecal inflammation in these mice. Data using Caco-2 cells revealed that fructose may counteract the increase in inflammation-induced permeability, strengthening this lack of association between fructose and alteration of the intestinal paracellular permeability. To the opposite glucose intake was associated with a clear increase in paracellular permeability in the jejunum and the cecum and a strong inflammation in the cecum likely resulting from changes in the microbiota composition.

Our investigation of the consequence of fructose on intestinal paracellular permeability was motivated by strong evidence from mice models fed with high amounts of fructose that fructose triggers the disruption of intestinal TJ protein expression, especially occludin, ZO1, and claudin2 (29, 32, 34, 62). In our current study, despite a minor decrease in occludin and claudin2 expression in the cecum in response to fructose intake, these changes were not associated with the alteration of intestinal permeability. In the cecum, while fructose consumption is associated with an increase in expression of Il13, Tnfa, and Ifnγ in a range similar to what is observed in response to glucose intake, the paracellular permeability remains unchanged in the mice receiving fructose when compared to the control group and increased only in the cecum of the glucose mice. The ability of pro-inflammatory cytokines to regulate TJ protein expression or assembly and to modulate epithelial permeability has been well described (22, 57, 63, 64). IL13 is known to increase the paracellular permeability through claudin2 (57, 65) while TNFα and IFNγ required the activation of the MLCK pathway (66). TNFα and IFNγ stimulate MLCK mRNA transcription, protein expression and activity that in turn activate the phosphorylation of the myosin light chain (MLC). The phosphorylated form of MLC results in the contraction of peri-junctional actinomyosin filaments and the TJ opening (22, 60, 66–68). This is coherent with the change in paracellular permeability observed in the cecum of the mice consuming glucose since the increase in TNFα and IFNγ was associated with a higher mRNA and protein expression of MLCK. However, even in a similar configuration, the mice consuming fructose failed to increase their intestinal epithelial paracellular permeability in the cecum. We also found *in vitro* that barrier

permeability alteration induced by IFNγ/TNFα develops less rapidly when Caco-2 cells were cultured in the presence of fructose when compared to glucose. Thus, taken together, these data suggest that glucose, but not fructose, enhances the alteration intestinal paracellular permeability in a pro-inflammatory context. The mechanism underlying this finding remains to be clarified and may differ in the small intestine and in the cecum where the transport and metabolism efficacy of glucose and/or fructose are likely different. The phosphorylation of MLC by MLCK and subsequent actomyosin contraction is an ATP-dependent process (69). Unlike glucose-metabolizing enzymes, the metabolism of fructose results in ATP depletion due to the lack of control of the first steps of the fructose metabolism by KHK and aldolase (70). This depletion in ATP had been shown in fructose metabolizing tissues such as renal tubules (71, 72), liver (73), and intestine (74). Thus, in the enterocytes when the fructose transportation and metabolism is high, as in the small intestine exposed to fructose, the diminution of ATP levels may prevent ATP-dependent actomyosin contraction process. The sugar metabolism appears necessary for pro-inflammatory cytokine-induced permeability changes. Therefore, in the cecum, a lower absorption and metabolism of fructose than glucose by the epithelial cells may also contribute to reduce the impact of pro-inflammatory cytokines on intestinal permeability in that specific region.

Other factors known to participate in the regulation of the intestinal permeability may be involved in the weakening effects of inflammation on paracellular permeability in the presence of fructose *in vivo*. In the past few years, several studies have demonstrated that EGCs are involved in maintaining gut homeostasis (75). GFAP is a marker of the enteric glia (76, 77) and intestinal increase in GFAP protein expression has been reported to be a sign of reactive gliosis (78). Active gliosis has been observed in the gut of patients with inflammatory bowel disease (79, 80) and *in vitro* TFNα induced increase in GFAP level in EGC (77). Since ablation of GFAP-positive EGC resulted in severe gut inflammation (3, 79, 81), it had been proposed that increase in GFAP and reactive gliosis preserved the intestinal epithelium integrity, even if a recent study challenged this hypothesis (82). In our study, fructose-induced GFAP may be a sign of active gliosis, which one deployed its protective effects on the integrity of the intestinal epithelium *in vivo* and limits the deleterious effects of fructose-induced inflammation on intestinal permeability *in vivo*.

Previous studies showed that chronic intake of high level of fructose (about 65%) or of fructose + high fat diet was associated with a significant increase in intestinal permeability (29, 34) while intake of a moderate amount of fructose was not (83). Chronic intake of high level of fructose is often associated with an increased glycemia. Recently, hyperglycemia was demonstrated as a major trigger of intestinal permeability increase (28). This glycemia-induced increase in intestinal permeability may explain the dissimilar effects of fructose on intestinal permeability obtained in our study and the one observed by others. More importantly, this hypothesis suggests that the increase in gut permeability does not precede the low-grade inflammation and
glucose intolerance often observed in response to dietary fructose. On the contrary, the alteration of the gut permeability could be one of the consequences of the low-grade inflammation and glucose intolerance as published recently (28).

Interestingly glucose and fructose drink intake led to different intestinal inflammation profile in the various regions of the GI tract. Recent studies revealed the metabolic reprogramming of immune cells in response to sugars (84, 85). Fructose and glucose absorption take place mainly in the proximal intestine (duodenum and jejunum). Their trans-epithelial transport is ensured at the apical membrane of the enterocytes by the GLUT5 and SGLT1 transporters, respectively, and by GLUT2 at the basolateral side (86). Therefore, after ingestion of food and drinks enriched in sugar, the highest concentrations of glucose and fructose are found in the jejunum (87, 88). Regardless of those high concentrations, fructose and glucose had almost no effect on the cytokine expression levels in the jejunum. Only glucose intake was associated with an increase in *Il1β* mRNA levels suggesting the activation of the macrophages. Conversely, a robust inflammation was observed in the cecum in response to both glucose and fructose intake. Based on the profile of cytokine expression, glucose and fructose intake may have activated the immune response involving the lymphocytes Type 1 helper (Th1) or the innate lymphoid cells (ILC1) producing TNFα and IFNγ in the cecum (89). The lymphocytes Type 2 helper (Th2) or the ILC2 producing Il13 may also be involved. In addition, glucose but not fructose may activate the lymphocytes Type 17 helper (Th17) producing IL22. The increase in *Il10* expression suggested also the possible activation of macrophages and regulatory T cells (Treg) in the lamina propria in the response to glucose and fructose intake. However, the direct role of the sugars or the indirect role of the microbiota in the response observed in our study remain to be demonstrated. Intestinal transport of fructose is poorly efficient when compared to glucose and a substantial fraction of fructose overspills in the distal parts of the GI where it is metabolized by the bacteria (37, 48). Recent studies clearly demonstrate the link between diet and microbiota in the enhancement of the gut inflammation, and more specifically, between microbiota and colitis suspectibility in response to glucose (83, 90). We propose that the adaptation of the cecal ecosystem to glucose and fructose intake, shown by the change in β-diversity, plays a role in the onset of cecal inflammation. Among the bacteria tested *in vitro* in the current study, glucose and even fructose can support bacterial growth. The most prominent family affected by glucose, and to a lesser extent by fructose, was the *Desulfovibrionaceae*. Interestingly, *Desulfovibrionaceae* are endotoxin producers (91) and have been linked to glucose tolerance in response to Western diet intake in mice (92) and to obesity in human (93). Moreover, *Desulfovibrionaceae* are sulfate-reducing bacteria that generate hydrogen sulfide (H₂S) (94) and the abundance of H₂S-producing bacteria has been correlated to intestinal inflammation, activation of immune cells, and alteration of permeability (95–97). Intake of glucose was also characterized by an enrichment of *Lachnospiraceae_NK4A136 group*, which has been reported to increase in rodent model of obesity and colitis (98, 99). *Lachnospiraceae* produce butyrate, a short-chain fatty acid

known for its beneficial effects on host health. However, *Lachnospiraceae* increased abundance has been also positively associated with several diseases (100). Interestingly, the response of intestinal epithelial cells to butyrate depends on the presence or absence of other energetic substrates: while butyrate promotes cell growth in the absence of glucose, it stimulates apoptosis at similar concentration when glucose is also available (101). This latter situation may resemble what occurred in the glucose fed mice in our study. Finally, in agreement with one earlier study (48) but in contrast with another (83), we found that mice consuming fructose displayed augmentation of *Lactobacillaceae*, which have been shown to exert health benefits including enhancement of epithelial barrier function and modulation of immune responses in rodent and human (100). The Lactobacilli may protect the epithelial barrier by inducing mucin secretion (102), stabilizing the tight junctions (103), reducing the apoptosis of epithelial cells (104) or supporting the proliferation of intestinal stem cells (105). Therefore, in our study, fructose-induced *Lactobacillaceae* may prevent alteration of the gut barrier function in response to fructose intake.

This study provides strong evidence that physiological amounts of fructose do not alter the intestinal paracellular permeability in any of the regions of the GI tract despite an increase in cecal epithelium inflammation and in circulating levels of IL6. Our data strongly suggest that alteration of intestinal permeability does not precede but follows the onset of metabolic outcome (low-grade inflammation and hyperglycemia) associated with chronic fructose consumption. We have also demonstrated that despite being absorbed in the small intestine, glucose intake has major harmful effects on the intestinal paracellular permeability of the cecum where it may interact with the microbiota. In particular, glucose-induced increased abundance of bacteria of *Desulfovibrionaceae* and *Lachnospiraceae_NK4A136 group* families might participate to the deleterious outcome of high glucose consumption on the intestinal epithelium.

## DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in Data INRAE Omic dataverse repository, https://doi.org/10.15454/3LBOIS.

## ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee in Animal Experiment of INRA Jouy-en-Josas (Comethea, registration number: APAFIS#1620-2015102618572930v2).

## AUTHOR CONTRIBUTIONS

The authors' responsibilities were as follows: XZ, CH, and VD designed the research. XZ, FB-C, CH, and VD conducted the research. XZ, CH, MMo, MMa, and VD analyzed the data.
XZ and VD wrote the manuscript. XZ, CH, NL, and VD contributed to the discussion. All authors contributed to the article and approved the submitted version.

## ACKNOWLEDGMENTS

This work was supported by grant from Institut Benjamin Delessert. China Scholarship Council (CSC) and INRAE funded Xufei Zhang PhD fellowships. We are grateful to the

INRAE MIGALE bioinformatics platform (http://migale.jouy.inra.fr/) for providing computational resources, to the Genotoul high-throughput sequencing platform.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.742584/full#supplementary-material

## REFERENCES

1. Siervo M, Montagnese C, Mathers JC, Soroka KR, Stephan BC, Wells JC. Sugar Consumption and Global Prevalence of Obesity and Hypertension: An Ecological Analysis. *Public Health Nutr* (2014) 17:587-96. doi: 10.1017/S1368980013000141

2. Bhupathiraju SN, Tobias DK, Malik VS, Pan A, Hruby A, Manson JE, et al. Glycemic Index, Glycemic Load, and Risk of Type 2 Diabetes: Results From 3 Large US Cohorts and an Updated Meta-Analysis. *Am J Clin Nutr* (2014) 100:218-32. doi: 10.3945/ajcn.113.079533

3. Basu S, McKee M, Galea G, Stuckler D. Relationship of Soft Drink Consumption to Global Overweight, Obesity, and Diabetes: A Cross-National Analysis of 75 Countries. *Am J Public Health* (2013) 103:2071-7. doi: 10.2105/AJPH.2012.300974

4. Te Morenga L, Mallard S, Mann J. Dietary Sugars and Body Weight: Systematic Review and Meta-Analyses of Randomised Controlled Trials and Cohort Studies. *BMJ (Clinical Res)* (2012) 346:e7492. doi: 10.1136/bmj.e7492

5. Bray GA, Popkin BM. Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes? Health Be Damned! Pour on the Sugar. *Diabetes Care* (2014) 37:950-6. doi: 10.2337/dc13-2085

6. Sundborn G, Thornley S, Merriman TR, Lang B, King C, Lanaspa MA, et al. Are Liquid Sugars Different From Solid Sugar in Their Ability to Cause Metabolic Syndrome? *Obes (Silver Spring Md)* (2019) 27:879-87. doi: 10.1002/oby.22472

7. Stanhope KL, Havel PJ. Endocrine and Metabolic Effects of Consuming Beverages Sweetened With Fructose, Glucose, Sucrose, or High-Fructose Corn Syrup. *Am J Clin Nutr* (2008) 88:1733s-7s. doi: 10.3945/ajcn.2008.25825D

8. Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, et al. Consumption of Fructose-Sweetened Beverages for 10 Weeks Reduces Net Fat Oxidation and Energy Expenditure in Overweight/Obese Men and Women. *Eur J Clin Nutr* (2012) 66:201-8. doi: 10.1038/ejcn.2011.159

9. Tappy L. Metabolism of Sugars: A Window to the Regulation of Glucose and Lipid Homeostasis by Splanchnic Organs. *Clin Nutr (Edinburgh Scotland)* (2021) 40:1691-8. doi: 10.1016/j.clnu.2020.12.022

10. Tappy L, Lé KA. Metabolic Effects of Fructose and the Worldwide Increase in Obesity. *Physiol Rev* (2010) 90:23-46. doi: 10.1152/physrev.00019.2009

11. Dallmeier D, Larson MG, Vasan RS, Keaney JF Jr, Fontes JD, Meigs JB, et al. Metabolic Syndrome and Inflammatory Biomarkers: A Community-Based Cross-Sectional Study at the Framingham Heart Study. *Diabetol Metab Syndrome* (2012) 4:28. doi: 10.1186/1758-5996-4-28

12. Rastelli M, Knauf C, Cani PD. Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders. *Obes (Silver Spring Md)* (2018) 26:792-800. doi: 10.1002/oby.22175

13. Phillips CM, Chen LW, Heude B, Bernard JY, Harvey NC, Duijts L, et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review. *Nutrients* (2019) 11(8):1873. doi: 10.3390/nu11081873

14. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of Human Gut Microbiome Correlates With Metabolic Markers. *Nature* (2013) 500:541-6. doi: 10.1038/nature12506

15. Laukoetter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babbin BA, et al. JAM-A Regulates Permeability and Inflammation in the Intestine *In Vivo. J Exp Med* (2007) 204:3067-76. doi: 10.1084/jem.20071416

16. Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, et al. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. *Gastroenterology* (2016) 151:733-46.e12. doi: 10.1053/j.gastro.2016.06.022

17. Marchiando AM, Shen L, Graham WV, Weber CR, Schwarz BT, Austin JR2nd, et al. Caveolin-1-Dependent Occludin Endocytosis Is Required for TNF-Induced Tight Junction Regulation *In Vivo. J Cell Biol* (2010) 189:111-26. doi: 10.1083/jcb.200902153

18. Sakakibara A, Furuse M, Saitou M, Ando-Akatsuka Y, Tsukita S. Possible Involvement of Phosphorylation of Occludin in Tight Junction Formation. *J Cell Biol* (1997) 137:1393-401. doi: 10.1083/jcb.137.6.1393

19. Suzuki T, Elias BC, Seth A, Shen L, Turner JR, Giorgianni F, et al. PKC Eta Regulates Occludin Phosphorylation and Epithelial Tight Junction Integrity. *Proc Natl Acad Sci USA* (2009) 106:61-6. doi: 10.1073/pnas.0802741106

20. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, et al. Inflammatory Processes Have Differential Effects on Claudins 2, 3 and 4 in Colonic Epithelial Cells. *Lab Invest; J Tech Methods Pathol* (2005) 85:1139-62. doi: 10.1038/labinvest.3700316

21. Turner JR, Buschmann MM, Romero-Calvo I, Sailer A, Shen L. The Role of Molecular Remodeling in Differential Regulation of Tight Junction Permeability. *Semin Cell Dev Biol* (2014) 36:204-12. doi: 10.1016/j.semimet.2014.09.022

22. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-Gamma and Tumor Necrosis Factor-Alpha Synergize to Induce Intestinal Epithelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase Expression. *Am J Pathol* (2005) 166:409-19. doi: 10.1016/S0002-9440(10)62264-X

23. Neunlist M, Rolli-Derkinderen M, Latorre R, Van Landeghem L, Coron E, Derkinderen P, et al. Enteric Glial Cells: Recent Developments and Future Directions. *Gastroenterology* (2014) 147:1230-7. doi: 10.1053/j.gastro.2014.09.040

24. Turner JR, Black ED, Ward J, Tse CM, Uchwat FA, Alli HA, et al. Transepithelial Resistance can be Regulated by the Intestinal Brush-Border Na(+)/H(+) Exchanger NHE3. *Am J Physiol Cell Physiol* (2000) 279:C1918-24. doi: 10.1152/ajpcell.2000.279.6.C1918

25. Fihn BM, Sjöqvist A, Jodal M. Permeability of the Rat Small Intestinal Epithelium Along the Villus-Crypt Axis: Effects of Glucose Transport. *Gastroenterology* (2000) 119:1029-36. doi: 10.1053/gast.2000.18148

26. Sadowski DC, Meddings JB. Luminal Nutrients Alter Tight-Junction Permeability in the Rat Jejunum: An *In Vivo* Perfusion Model. *Can J Physiol Pharmacol* (1993) 71:835-9. doi: 10.1139/y93-125

27. Turner JR, Cohen DE, Mrsny RJ, Madara JL. Noninvasive *In Vivo* Analysis of Human Small Intestinal Paracellular Absorption: Regulation by Na+-Glucose Cotransport. *Digest Dis Sci* (2000) 45:2122-6. doi: 10.1023/A:1026682900586

28. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, et al. Hyperglycemia Drives Intestinal Barrier Dysfunction and Risk for Enteric Infection. *Sci (New York NY)* (2018) 359:1376-83. doi: 10.1126/science.aar3318

29. Do MH, Lee E, Oh MJ, Kim Y, Park HY. High-Glucose or -Fructose Diet Cause Changes of the Gut Microbiota and Metabolic Disorders in Mice Without Body Weight Change. *Nutrients* (2018) 10(6):761. doi: 10.3390/nu10060761

30. Kuzma JN, Cromer G, Hagman DK, Breymeyer KL, Roth CL, Foster-Schubert KE, et al. No Differential Effect of Beverages Sweetened With
Fructose, High-Fructose Corn Syrup, or Glucose on Systemic or Adipose Tissue Inflammation in Normal-Weight to Obese Adults: A Randomized Controlled Trial. *Am J Clin Nutr* (2016) 104:306-14. doi: 10.3945/ajcn.115.129650

31. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I. Serotonin Reuptake Transporter (SERT) Plays a Critical Role in the Onset of Fructose-Induced Hepatic Steatosis in Mice. *Am J Physiol Gastrointestinal Liver Physiol* (2010) 298:G335-44. doi: 10.1152/ajpgi.00088.2009

32. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin Protects Against the Development of Fructose-Induced Steatosis in Mice: Role of the Intestinal Barrier Function. *Lab Invest; J Tech Methods Pathol* (2012) 92:1020-32. doi: 10.1038/labinvest.2012.75

33. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-Like Receptor 4 Is Involved in the Development of Fructose-Induced Hepatic Steatosis in Mice. *Hepatol (Baltimore Md)* (2009) 50:1094-104. doi: 10.1002/hep.23122

34. Volynets V, Louis S, Pretz D, Lang L, Ostaff MJ, Wehkamp J, et al. Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented With Fructose. *J Nutr* (2017) 147:770-80. doi: 10.3945/jn.116.242859

35. Asghar ZA, Cusumano A, Yan Z, Remedi MS, Moley KH. Reduced Islet Function Contributes to Impaired Glucose Homeostasis in Fructose-Fed Mice. *Am J Physiol Endocrinol Metab* (2017) 312:E109-16. doi: 10.1152/ajpendo.00279.2016

36. Douard V, Ferraris RP. Regulation of the Fructose Transporter GLUT5 in Health and Disease. *Am J Physiol Endocrinol Metab* (2008) 295:E227-37. doi: 10.1152/ajpendo.90245.2008

37. Jang C, Hui S, Lu W, Cowan AJ, Morscher RJ, Lee G, et al. The Small Intestine Converts Dietary Fructose Into Glucose and Organic Acids. *Cell Metab* (2018) 27:351-61.e3. doi: 10.1016/j.cmet.2017.12.016

38. De Souza L, Barros WM, De Souza RM, Delanogare E, Machado AE, Braga SP, et al. Impact of Different Fructose Concentrations on Metabolic and Behavioral Parameters of Male and Female Mice. *Physiol Behav* (2021) 228:113187. doi: 10.1016/j.physbeh.2020.113187

39. Ishimoto T, Lanaspa MA, Le MT, Garcia GE, Diggle CP, Maclean PS, et al. Opposing Effects of Fructokinase C and A Isoforms on Fructose-Induced Metabolic Syndrome in Mice. *Proc Natl Acad Sci USA* (2012) 109:4320-5. doi: 10.1073/pnas.1119908109

40. Jürgens H, Haass W, Castañeda TR, Schürmann A, Koebnick C, Dombrowski F, et al. Consuming Fructose-Sweetened Beverages Increases Body Adiposity in Mice. *Obes Res* (2005) 13:1146-56. doi: 10.1038/oby.2005.136

41. Beaumont M, Jaoui D, Douard V, Mat D, Koeth F, Goustad B, et al. Structure of Protein Emulsion in Food Impacts Intestinal Microbiota, Caecal Luminal Content Composition and Distal Intestine Characteristics in Rats. *Mol Nutr Food Res* (2017) 61:1700078. doi: 10.1002/mnfr.201700078

42. Mayeur C, Gratadoux JJ, Bridonneau C, Chegdani F, Larroque B, Kapel N, et al. Faecal D/L Lactate Ratio Is a Metabolic Signature of Microbiota Imbalance in Patients With Short Bowel Syndrome. *PloS One* (2013) 8: e54335. doi: 10.1371/journal.pone.0054335

43. Escudié F, Auer L, Bernard M, Mariadassou M, Cauquil L, Vidal K, et al. FROGS: Find, Rapidly, OTUs With Galaxy Solution. *Bioinf (Ox Engl)* (2018) 34:1287-94. doi: 10.1093/bioinformatics/btx791

44. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, et al. Quality-Filtering Vastly Improves Diversity Estimates From Illumina Amplicon Sequencing. *Nat Methods* (2013) 10:57-9. doi: 10.1038/ nmeth.2276

45. Fite A, Macfarlane GT, Cummings JH, Hopkins MJ, Kong SC, Furrie E, et al. Identification and Quantitation of Mucosal and Faecal Desulfofibrios Using Real Time Polymerase Chain Reaction. *Gut* (2004) 53:523-9. doi: 10.1136/ gut.2003.031245

46. Yu S, Balasubramanian I, Laubitz D, Tong K, Bandyopadhyay S, Lin X, et al. Paneth Cell-Derived Lysozyme Defines the Composition of Mucolytic Microbiota and the Inflammatory Tone of the Intestine. *Immunity* (2020) 53:398-416.e8. doi: 10.1016/j.immuni.2020.07.010

47. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J, Mondot S, et al. Comparative Assessment of Human and Farm Animal Faecal Microbiota

Using Real-Time Quantitative PCR. *FEMS Microbiol Ecol* (2009) 68:351-62. doi: 10.1111/j.1574-6941.2009.00671.x

48. Zhang X, Grosfeld A, Williams E, Vasiliauskas D, Barretto S, Smith L, et al. Fructose Malabsorption Induces Cholecystokinin Expression in the Ileum and Cecum by Changing Microbiota Composition and Metabolism. *FASEB J Off Publ Fed Am Societies Exp Biol* (2019) 33:7126-42. doi: 10.1096/ fj.201801526RR

49. Kozich JJ, Westcott SL, Baxter NT, Highland SK, Schloss PD. Development of a Dual-Index Sequencing Strategy and Curation Pipeline for Analyzing Amplicon Sequence Data on the MiSeq Illumina Sequencing Platform. *Appl Environ Microbiol* (2013) 79:5112-20. doi: 10.1128/ AEM.01043-13

50. Wickham H. *Ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag (2009).

51. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2. *Genome Biol* (2014) 15:550. doi: 10.1186/s13059-014-0550-8

52. Chen L, Reeve J, Zhang L, Huang S, Wang X, Chen J. GMPR: A Robust Normalization Method for Zero-Inflated Count Data With Application to Microbiome Sequencing Data. *PeerJ* (2018) 6:e4600. doi: 10.7717/ peerj.4600

53. Rohart F, Gautier B, Singh A, Lè Cao K-A. Mixomics: An R Package for 'Omics Feature Selection and Multiple Data Integration. *PloS Comput Biol* (2017) 13:e1005752. doi: 10.1371/journal.pcbi.1005752

54. Lè Cao KA, González I, Déjean S. Integromics: An R Package to Unravel Relationships Between Two Omics Datasets. *Bioinf (Oxford England)* (2009) 25:2855-6. doi: 10.1093/bioinformatics/btp515

55. Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, et al. Low-Grade Inflammation, Diet Composition and Health: Current Research Evidence and Its Translation. *Br J Nutr* (2015) 114:999-1012. doi: 10.1017/ S0007114515002093

56. Mohammad S, Thiemann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. *Front Immunol* (2020) 11:594150. doi: 10.3389/fimmu.2020.594150

57. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 Is the Key Effector Th2 Cytokine in Ulcerative Colitis That Affects Epithelial Tight Junctions, Apoptosis, and Cell Restitution. *Gastroenterology* (2005) 129:550-64. doi: 10.1016/j.gastro.2005.05.002

58. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 Cell Line as a Model of the Intestinal Barrier: Influence of Cell and Culture-Related Factors on Caco-2 Cell Functional Characteristics. *Cell Biol Toxicol* (2005) 21:1-26. doi: 10.1007/s10565-005-0085-6

59. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, et al. A Membrane-Permeant Peptide That Inhibits MLC Kinase Restores Barrier Function in *In Vitro* Models of Intestinal Disease. *Gastroenterology* (2002) 123:163-72. doi: 10.1053/gast.2002.34235

60. Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-{Alpha} Modulation of Caco-2 Intestinal Epithelial Tight Junction Barrier: Role of Myosin Light-Chain Kinase Protein Expression. *Am J Physiol Gastrointestinal Liver Physiol* (2005) 288:G422-30. doi: 10.1152/ajpgi. 00412.2004

61. Schmitt CC, Aranias T, Viel T, Chateau D, Le Gall M, Waligora-Dupriet AJ, et al. Intestinal Validation of the Glucose Transporter GLUT2 Delays Tissue Distribution of Glucose and Reveals an Unexpected Role in Gut Homeostasis. *Mol Metab* (2017) 6:61-72. doi: 10.1016/j.molmet.2016.10.008

62. Sellmann C, Priebes J, Landmann M, Degen C, Engstler AJ, Jin CJ, et al. Diets Rich in Fructose, Fat or Fructose and Fat Alter Intestinal Barrier Function and Lead to the Development of Nonalcoholic Fatty Liver Disease Over Time. *J Nutr Biochem* (2015) 26:1183-92. doi: 10.1016/j.jnutbio.2015.05.011

63. Madara JL, Stafford J. Interferon-Gamma Directly Affects Barrier Function of Cultured Intestinal Epithelial Monolayers. *J Clin Invest* (1989) 83:724-7. doi: 10.1172/JCI113938

64. Walsh SV, Hopkins AM, Nusrat A. Modulation of Tight Junction Structure and Function by Cytokines. *Advanced Drug Delivery Rev* (2000) 41:303-13. doi: 10.1016/S0169-409X(00)00048-X

65. Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y, et al. Epithelial Myosin Light Chain Kinase Activation Induces Mucosal Interleukin-13
Expression to Alter Tight Junction Ion Selectivity. *J Biol Chem* (2010) 285:12037-46. doi: 10.1074/jbc.M109.064808

66. Ye D, Ma I, Ma TY. Molecular Mechanism of Tumor Necrosis Factor-Alpha Modulation of Intestinal Epithelial Tight Junction Barrier. *Am J Physiol Gastrointestinal Liver Physiol* (2006) 290:G496-504. doi: 10.1152/ajpgi.00318.2005

67. Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, Wang Y, et al. Tumor Necrosis Factor-Induced Long Myosin Light Chain Kinase Transcription Is Regulated by Differentiation-Dependent Signaling Events. Characterization of the Human Long Myosin Light Chain Kinase Promoter. *J Biol Chem* (2006) 281:26205-15. doi: 10.1074/jbc.M602164200

68. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, et al. IFN-Gamma-Induced TNFR2 Expression Is Required for TNF-Dependent Intestinal Epithelial Barrier Dysfunction. *Gastroenterology* (2006) 131:1153-63. doi: 10.1053/j.gastro.2006.08.022

69. Shen Q, Rigor RR, Pivetti CD, Wu MH, Yuan SY. Myosin Light Chain Kinase in Microvascular Endothelial Barrier Function. *Cardiovasc Res* (2010) 87:272-80. doi: 10.1093/cvr/cvq144

70. Mayes PA. Intermediary Metabolism of Fructose. *Am J Clin Nutr* (1993) 58:754s-65s. doi: 10.1093/ajcn/58.5.754S

71. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, et al. Fulminant Jejuno-Ileitis Following Ablation of Enteric Glia in Adult Transgenic Mice. *Cell* (1998) 93:189-201. doi: 10.1016/S0092-8674(00) 81571-8

72. Lanaspa MA, Ishimoto T, Cicerchi C, Tamura Y, Roncal-Jimenez CA, Chen W, et al. Endogenous Fructose Production and Fructokinase Activation Mediate Renal Injury in Diabetic Nephropathy. *J Am Soc Nephrol JASN* (2014) 25:2526-38. doi: 10.1681/ASN.2013080901

73. Lanaspa MA, Andres-Hernando A, Orlicky DJ, Cicerchi C, Jang C, Li N, et al. Ketohexokinase C Blockade Ameliorates Fructose-Induced Metabolic Dysfunction in Fructose-Sensitive Mice. *J Clin Invest* (2018) 128:2226-38. doi: 10.1172/JCI94427

74. Tharabenjasin P, Douard V, Patel C, Krishnamra N, Johnson RJ, Zuo J, et al. Acute Interactions Between Intestinal Sugar and Calcium Transport *In Vitro*. *Am J Physiol Gastrointestinal liver Physiol* (2014) 306:G1-12. doi: 10.1152/ajpgi.00263.2013

75. Neunlist M, Van Landeghem L, Mahé MM, Derkinderen P, des Varannes SB, Rolli-Derkinderen M. The Digestive Neuronal-Glial-Epithelial Unit: A New Actor in Gut Health and Disease. *Nat Rev Gastroenterol Hepatol* (2013) 10:90-100. doi: 10.1038/nrgastro.2012.221

76. Boesmans W, Lasrado R, Vanden Berghe P, Pachnis V. Heterogeneity and Phenotypic Plasticity of Glial Cells in the Mammalian Enteric Nervous System. *Glia* (2015) 63:229-41. doi: 10.1002/glia.22746

77. von Boyen GB, Steinkamp M, Reinshagen M, Schäfer KH, Adler G, Kirsch J. Proinflammatory Cytokines Increase Glial Fibrillary Acidic Protein Expression in Enteric Glia. *Gut* (2004) 53:222-8. doi: 10.1136/gut.2003.012625

78. Yang Z, Wang KK. Glial Fibrillary Acidic Protein: From Intermediate Filament Assembly and Gliosis to Neurobiomarker. *Trends Neurosci* (2015) 38:364-74. doi: 10.1016/j.tins.2015.04.003

79. Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H, et al. Enterocolitis Induced by Autoimmune Targeting of Enteric Glial Cells: A Possible Mechanism in Crohn's Disease? *Proc Natl Acad Sci USA* (2001) 98:13306-11. doi: 10.1073/pnas.231474098

80. von Boyen GB, Schulte N, Pflüger C, Spaniol U, Hartmann C, Steinkamp M. Distribution of Enteric Glia and GDNF During Gut Inflammation. *BMC Gastroenterol* (2011) 11:3. doi: 10.1186/1471-230X-11-3

81. Aubé AC, Cabarrocas J, Bauer J, Philippe D, Aubert P, Doulay F, et al. Changes in Enteric Neurone Phenotype and Intestinal Functions in a Transgenic Mouse Model of Enteric Glia Disruption. *Gut* (2006) 55:630-7. doi: 10.1136/gut.2005.067595

82. Rao M, Rastelli D, Dong L, Chiu S, Setlik W, Gershon MD, et al. Enteric Glia Regulate Gastrointestinal Motility But Are Not Required for Maintenance of the Epithelium in Mice. *Gastroenterology* (2017) 153:1068-81.e7. doi: 10.1053/j.gastro.2017.07.002

83. Khan S, Waliullah S, Godfrey V, Khan MAW, Ramachandran RA, Cantarel BL, et al. Dietary Simple Sugars Alter Microbial Ecology in the Gut and

Promote Colitis in Mice. *Sci Transl Med* (2020) 12(567). doi: 10.1126/ scitranslmed.aya6218

84. Jones N, Blagih J, Zani F, Rees A, Hill DG, Jenkins BJ, et al. Fructose Reprogrammes Glutamine-Dependent Oxidative Metabolism to Support LPS-Induced Inflammation. *Nat Commun* (2021) 12:1209. doi: 10.1038/ s41467-021-21461-4

85. Sullivan ZA, Khoury-Hanold W, Lim J, Smillie C, Biton M, Reis BS, et al. γδ T Cells Regulate the Intestinal Response to Nutrient Sensing. *Sci (New York NY)* (2021) 371(6535). doi: 10.1126/science.aba8310

86. Davidson NO, Hausman AM, Ifkovits CA, Buse JB, Gould GW, Burant CF, et al. Human Intestinal Glucose Transporter Expression and Localization of GLUT5. *Am J Physiol* (1992) 262:C795-800. doi: 10.1152/ajpcell. 1992.262.3.C795

87. Ferraris RP, Yasharpour S, Lloyd KC, Mirzayan R, Diamond JM. Luminal Glucose Concentrations in the Gut Under Normal Conditions. *Am J Physiol Gastrointest Liver Physiol* (1990) 259:G822-37. doi: 10.1152/ajpgi. 1990.259.5.G822

88. David ES, Cingari DS, Ferraris RP. Dietary Induction of Intestinal Fructose Absorption in Weaning Rats. *Pediatr Res* (1995) 37:777-82. doi: 10.1203/ 00006450-199506000-00017

89. Xue X, Falcon DM. The Role of Immune Cells and Cytokines in Intestinal Wound Healing. *Int J Mol Sci* (2019) 20(23):6097. doi: 10.3390/ ijms20236097

90. Müller VM, Zietek T, Rohm F, Fiamoncini J, Lagkouvaridis I, Haller D, et al. Gut Barrier Impairment by High-Fat Diet in Mice Depends on Housing Conditions. *Mol Nutr Food Res* (2016) 60:897-908. doi: 10.1002/ mnfr.201500775

91. Zhang-Sun W, Augusto LA, Zhao L, Caroff M. Desulfofibrio Desulfuricants Isolates From the Gut of a Single Individual: Structural and Biological Lipid A Characterization. *FEBS Lett* (2015) 589:165-71. doi: 10.1016/ j.febslet.2014.11.042

92. Zhang C, Zhang M, Wang S, Han R, Cao Y, Hua W, et al. Interactions Between Gut Microbiota, Host Genetics and Diet Relevant to Development of Metabolic Syndromes in Mice. *ISME J* (2010) 4:232-41. doi: 10.1038/ ismej.2009.112

93. Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, et al. A Gut Microbiota-Targeted Dietary Intervention for Amelioration of Chronic Inflammation Underlying Metabolic Syndrome. *FEMS Microbiol Ecol* (2014) 87:357-67. doi: 10.1111/j.1574-6941.12228

94. Montgomery AD, McLnerney MJ, Sublette KL. Microbial Control of the Production of Hydrogen Sulfide by Sulfate-Reducing Bacteria. *Biotechnol Bioeng* (1990) 35:533-9. doi: 10.1002/bit.260350512

95. Loubinoux J, Bronowicki JP, Pereira IA, Mougenel JL, Faou AE. Sulfate-Reducing Bacteria in Human Feces and Their Association With Inflammatory Bowel Diseases. *FEMS Microbiol Ecol* (2002) 40:107-12. doi: 10.1111/j.1574-6941.2002.tb00942.x

96. Lam YY, Ha CW, Hoffmann JM, Oscarsson J, Dinudom A, Mather TJ, et al. Effects of Dietary Fat Profile on Gut Permeability and Microbiota and Their Relationships With Metabolic Changes in Mice. *Obes (Silver Spring Md)* (2015) 23:1429-39. doi: 10.1002/oby.21122

97. Figliuolo VR, Dos Santos LM, Abalo A, Nanini H, Santos A, Brittes NM, et al. Sulfate-Reducing Bacteria Stimulate Gut Immune Responses and Contribute to Inflammation in Experimental Colitis. *Life Sci* (2017) 189:29-38. doi: 10.1016/j.lfs.2017.09.014

98. Cui H-X, Zhang L-S, Luo Y, Yuan K, Huang Z-Y, Guo Y. A Purified Anthraquinone-Glycoside Preparation From Rhubarb Ameliorates Type 2 Diabetes Mellitus by Modulating the Gut Microbiota and Reducing Inflammation. *Front Microbiol* (2019) 10:1423. doi: 10.3389/fmicb. 2019.01423

99. Guo S, Geng W, Chen S, Wang L, Rong X, Wang S, et al. Ginger Alleviates DSS-Induced Ulcerative Colitis Severity by Improving the Diversity and Function of Gut Microbiota. *Front Pharmacol* (2021) 12:632569. doi: 10.3389/fphar.2021.632569

100. Lebeer S, Vanderleyden J, De Keersmaeker SC. Genes and Molecules of Lactobacilli Supporting Probiotic Action. *Microbiol Mol Biol Rev MMBR* (2008) 72:728-64. doi: 10.1128/MMBR.00017-08

101. Singh B, Halestrap AP, Paraskeva C. Butyrate can Act as a Stimulator of Growth or Inducer of Apoptosis in Human Colonic Epithelial Cell Lines
Depending on the Presence of Alternative Energy Sources. *Carcinogenesis* (1997) 18:1265-70. doi: 10.1093/carcin/18.6.1265

102. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 Mucin Secretion Follows Adherence of Lactobacillus Strains to Intestinal Epithelial Cells *In Vitro*. *Gut* (2003) 52:827-33. doi: 10.1136/gut.52.6.827

103. Seth A, Yan F, Polk DB, Rao RK. Probiotics Ameliorate the Hydrogen Peroxide-Induced Epithelial Barrier Disruption by a PKC- and MAP Kinase-Dependent Mechanism. *Am J Physiol Gastrointestinal Liver Physiol* (2008) 294:G1060-9. doi: 10.1152/ajpgi.00202.2007

104. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and Growth. *Gastroenterology* (2007) 132:562-75. doi: 10.1053/j.gastro.2006.11.022

105. Hou Y, Wei W, Guan X, Liu Y, Bian G, He D, et al. A Diet-Microbial Metabolism Feedforward Loop Modulates Intestinal Stem Cell Renewal in the Stressed Gut. *Nat Commun* (2021) 12:271. doi: 10.1038/s41467-020-20673-4

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Monnoye, Mariadassou, Beguet-Crespel, Lapaque, Heberden and Douard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.